Investigational Drug Details
| Drug ID: | D159 |
| Drug Name: | Cephalexin |
| Synonyms: | |
| Type: | small molecule |
| DrugBank ID: | DB00567 |
| DrugBank Description: | Cephalexin is the first of the first generation cephalosporins.[A179071,A179074] This antibiotic contains a beta lactam and a dihydrothiazide.[A179071] Cephalexin is used to treat a number of susceptible bacterial infections through inhibition of cell wall synthesis.[A179083,Label] Cephalexin was approved by the FDA on 4 January 1971.[L6547] |
| PubChem ID: | 27447 |
| CasNo: | 15686-71-2 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [H][C@]12SCC(C)=C(N1C(=O)[C@H]2NC(=O)[C@H](N)C1=CC=CC=C1)C(O)=O |
| Structure: |
|
| InChiKey: | ZAIPMKNFIOOWCQ-UEKVPHQBSA-N |
| Molecular Weight: | 347.389 |
| DrugBank Targets: | Penicillin-binding protein 3; Penicillin-binding protein 2a; Penicillin-binding protein 1b; Penicillin-binding protein 2B; Penicillin-binding protein 1A |
| DrugBank MoA: | Cephalexin is a first generation cephalosporin antibiotic.[A179071,A179074] Cephalosporins contain a beta lactam and dihydrothiazide.[A179071] Unlike penicillins, cephalosprins are more resistant to the action of beta lactamase.[A179071] Cephalexin inhibits bacterial cell wall synthesis, leading breakdown and eventualy cell death.[Label] |
| DrugBank Pharmacology: | Cephalexin (also called Cefalexin) is a first generation cephalosporin antibiotic.[A179071,A179074] It is one of the most widely prescribed antibiotics, often used for the treatment of superficial infections that result as complications of minor wounds or lacerations.[Label] It is effective against most gram-positive bacteria through its inihibition of the cross linking reaction between N-acetyl muramicacid and N-acetylglucosamine in the cell wall, leading to cell lysis.[A179083] |
| DrugBank Indication: | Cephalexin is indicated for the treatment of certain infections caused by susceptible bacteria.[Label,L6550,L6553] These infections include respiratory tract infections, otitis media, skin and skin structure infections, bone infections, and genitourinary tract infections.[Label,L6550,L6553] |
| Targets: | |
| Therapeutic Category: | |
| Clinical Trial Progress: | |
| Latest Progress: |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L4019 | NCT02516150 | PHASE4 | COMPLETED | YES | 2016-03 | 2017-08-31 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name | |
|---|---|---|---|---|---|---|---|
| T04 | Peroxisome proliferator-activated receptor gamma | PPARG | AGONIST; MODULATOR; PARTIAL AGONIST; ANTAGONIST | Target is a single protein chain | P37231 | PPARG_HUMAN | Details |
| T47 | Sialin | SLC17A5 | Target is a single protein chain | Q9NRA2 | SLC17A5_HUMAN | Details | |
| T15 | Steryl-sulfatase | STS | INHIBITOR | Hydrolase | P08842 | STS_HUMAN | Details |
| Strategy ID | Strategy | Synonyms | Related Targets | Related Drugs |
|---|
| Article ID | PMID | Source | Title |
|---|